Signal Pharmaceuticals

Signal Pharmaceuticals was a biopharmaceutical company focused on the discovery and development of small molecule drugs that regulate signal transduction pathways. The company's research primarily targeted the JNK (c-Jun N-terminal kinase) and NF-kappaB pathways, which play critical roles in inflammation, oncology, and neurodegeneration. Founded in San Diego, Signal developed a proprietary platform to identify compounds that modulate gene expression by targeting specific intracellular signaling proteins. Their approach aimed to treat chronic diseases by intercepting the cellular signals that trigger disease progression. In 2000, the company was acquired by Celgene Corporation for approximately $200 million in stock. This acquisition provided Celgene with a robust kinase discovery platform and several promising lead compounds in the fields of cancer and inflammatory disease.